One Year Follow-up from RSV F-Protein Vaccine Candidate Phase 1 Elderly Trial Demonstrates Sustained Levels of Immune Response

Sustained levels of RSV F antibody and palivizumab-competing antibody responses demonstrated over a 4 to 6 month period  Results support accelerating development plans for “seasonal” elderly RSV vaccine  Phase 2 clinical trial in elderly anticipated to start in late-2014/early-2015 May 12, 2014 Novavax, Inc. today announced follow-up data from its dose-ranging Phase 1 clinical trial of its respiratory syncytial virus (RSV) …

Researchers Develop Key to Effective RSV Vaccine: HIV and influenza next up

Scientists from the Scripps Research Institute, Calafornia, US, have created vital ingredients for an effective vaccination against respiratory syncytial virus (RSV) through a new method they have developed for producing artificial proteins. As reported in Nature on February the 5th, using a ‘rational design’ method researchers produced designer proteins which stimulate the production of the desired virus-neutralizing antibodies for RSV in …

10 of the Most Important Diseases With No Licensed Vaccine

Vaccination has been successful at controlling many of the world’s diseases. However, there still remain many infectious diseases for which no licensed (US or EU) vaccine exists. Here I’ve selected 10 of them – arranged in no particular order – which I think are especially important. Click Next to read them > I look forward to hearing your thoughts. Next …